var data={"title":"Ondansetron: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Ondansetron: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6684?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">see &quot;Ondansetron: Drug information&quot;</a> and <a href=\"topic.htm?path=ondansetron-patient-drug-information\" class=\"drug drug_patient\">see &quot;Ondansetron: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203706\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Zofran;</li>\n      <li>Zofran ODT;</li>\n      <li>Zuplenz</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203707\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>ACT Ondansetron;</li>\n      <li>AG-Ondansetron;</li>\n      <li>Apo-Ondansetron;</li>\n      <li>Bio-Ondansetron;</li>\n      <li>Dom-Ondansetron;</li>\n      <li>IPG-Ondansetron;</li>\n      <li>JAMP-Ondansetron;</li>\n      <li>Mar-Ondansetron;</li>\n      <li>Mint-Ondansetron;</li>\n      <li>Mylan-Ondansetron;</li>\n      <li>NAT-Ondansetron;</li>\n      <li>Nu-Ondansetron;</li>\n      <li>Ondansetron Hydrochloride Dihydrate Injection;</li>\n      <li>Ondansetron Injection;</li>\n      <li>Ondansetron Injection USP;</li>\n      <li>Ondansetron-Omega;</li>\n      <li>Ondissolve ODF;</li>\n      <li>PHL-Ondansetron;</li>\n      <li>PMS-Ondansetron;</li>\n      <li>Priva-Ondansetron;</li>\n      <li>RAN-Ondansetron;</li>\n      <li>ratio-Ondansetron;</li>\n      <li>Sandoz-Ondansetron;</li>\n      <li>Sandoz-Ondansetron ODT;</li>\n      <li>Septa-Ondansetron;</li>\n      <li>Teva-Ondansetron;</li>\n      <li>Vanc-Ondansetron;</li>\n      <li>Zofran ODT</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060735\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">5-HT<sub>3</sub> Receptor Antagonist</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antiemetic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060729\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">see &quot;Ondansetron: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chemotherapy-induced nausea and vomiting, prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Infants &ge;6 months, Children, and Adolescents: 0.15 mg/kg/dose; maximum dose: 16 mg/dose; administer first dose 30 minutes before the start of chemotherapy with subsequent doses administered 4 and 8 hours after the first dose for 3 doses total</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Oral: <i>Moderately emetogenic antineoplastic therapy:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children 4 to 11 years: 4 mg beginning 30 minutes before chemotherapy; repeat 4 and 8 hours after initial dose, then 4 mg every 8 hours for 1 to 2 days after chemotherapy completed</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Children &ge;12 years and Adolescents: 8 mg beginning 30 minutes before chemotherapy; repeat dose 8 hours after initial dose, then 8 mg every 12 hours for 1 to 2 days after chemotherapy completed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-directed dosing: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Highly emetogenic antineoplastic therapy:</i> IV, Oral: 0.15 mg/kg/dose; maximum dose: 16 mg/dose; administer first dose before the start of chemotherapy and then every 8 hours (Dupuis 2013); a once-daily single dose of 0.3 mg/kg or 0.45 mg/kg (maximum dose: 16 mg) dependent upon emetogenic potential of chemotherapy has also been reported (Holdsworth 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Moderately emetogenic antineoplastic therapy:</i> IV, Oral: 0.15 mg/kg/dose; maximum dose: 8 mg/dose; administer first dose before the start of chemotherapy with subsequent doses every 12 hours (Dupuis 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Low emetogenic antineoplastic therapy:</i> IV, Oral: 0.3 mg/kg/dose once; maximum dose: 16 mg/dose; administered 30 minutes before the start of chemotherapy (Dupuis 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">BSA-directed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Highly emetogenic antineoplastic therapy:</i> Infants, Children, and Adolescents: IV, Oral: 5 mg/m<sup>2</sup>/dose; maximum dose: 16 mg/dose; administer first dose before the start of chemotherapy with subsequent doses administered every 8 hours (Dupuis 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Moderately emetogenic antineoplastic therapy:</i> Infants, Children, and Adolescents: IV, Oral: 5 mg/m<sup>2</sup>/dose; maximum dose: 8 mg/dose; administer first before the start of chemotherapy with subsequent doses every 12 hours (Dupuis 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Low emetogenic antineoplastic therapy:</i> Infants, Children, and Adolescents: IV, Oral: 10 mg/m<sup>2</sup>/dose once; maximum dose: 16 mg/dose; administered before the start of chemotherapy (Dupuis 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Cyclic vomiting syndrome (CVS); treatment of acute attack</b> Limited data available; dosing based on case reports and clinical experience: Children &gt;2 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Low dose: IV: 0.15 mg/kg every 4 hours as needed for up to 3 doses; maximum dose: 16 mg/dose (Fleisher 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">High dose: IV: 0.3 to 0.4 mg/kg/dose every 4 to 6 hours; maximum dose: 16 mg/dose (Li 2008); per manufacturer labeling, should not exceed 3 doses in a 24-hour period</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Gastroenteritis, acute; treatment:</b> <b>Note:</b> Routine use of ondansetron is not recommended in most cases of acute gastroenteritis (AAP 2004; CDC 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Infants and Children &ge;1 month: 0.15 or 0.3 mg/kg/dose once; maximum dose: 16 mg/dose (DeCamp 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Infants and Children 6 months to 10 years, &ge;8 kg (Freedman 2006):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">8 to 15 kg: 2 mg/dose once</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;15 to 30 kg: 4 mg/dose once</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;30 kg: 8 mg/dose once</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postoperative nausea and vomiting; prevention:</b> Administer immediately before or following induction of anesthesia, or postoperatively if the patient is symptomatic. Repeat doses given in response to inadequate control of nausea/vomiting from preoperative doses are generally ineffective.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants and Children: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&le;40 kg: 0.1 mg/kg/dose as a single dose; maximum dose: 4 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;40 kg: 4 mg/dose as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents: IM, IV: 4 mg/dose as a single dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Radiation-induced nausea and vomiting, prevention:</b> Limited data available: Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed dosing: Infants &ge;5 months, Children, and Adolescents: 0.2 mg/kg/dose (maximum dose: 8 mg/dose) administered every 8 hours throughout total body irradiation (TBI) prior to HSCT (n=68; mean age: 6.7 years; range: 5 months to 20 years); doses were generally rounded to 4 mg/dose in children 4 to 11 years and 8 mg/dose in children &ge;12 years and adolescents (Applegate 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate weight-based dosing: Children and Adolescents: 0.15 mg/kg/dose administered 3 to 4 times daily throughout TBI (n=33; mean age: 9 years; range: 13 months to 16 years) (Farah 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed dose: <b>Note:</b> Derived from rounding weight-based (0.2 mg/kg/dose) doses (Applegate 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children 4 to 11 years: 4 mg every 8 hours throughout total body irradiation (TBI) prior to HSCT</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children &ge;12 years and Adolescents: 8 mg every 8 hours throughout total body irradiation (TBI) prior to HSCT</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Alternate fixed-dosing: Children &ge;9 years and Adolescents: 8 mg every 12 hours on days of TBI prior to bone marrow transplantation (age range: 9 to 67 years; median age range: 39 to 49 years). <b>Note:</b> Administered in combination with dexamethasone (Bredeson 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chemotherapy-induced nausea and vomiting, prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 0.15 mg/kg/dose (maximum dose: 16 mg) over 15 minutes for 3 doses, beginning 30 minutes prior to chemotherapy, followed by subsequent doses 4 and 8 hours after the first dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Highly emetogenic chemotherapy:</i> 24 mg 30 minutes prior to the start of single-day chemotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Moderately emetogenic chemotherapy:</i> 8 mg beginning 30 minutes before chemotherapy; repeat dose 8 hours after initial dose, then 8 mg every 12 hours for 1 to 2 days after chemotherapy completed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postoperative nausea and vomiting (PONV), prevention: Note:</b> The manufacturer recommends administration immediately before induction of anesthesia; however, this has been shown not to be as effective as administration at the end of surgery (Sun 1997). Repeat doses given in response to inadequate control of nausea/vomiting from preoperative doses are generally ineffective.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM, IV: 4 mg as a single dose (over 2 to 5 minutes if given IV) administered ~30 minutes before the end of anesthesia</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 16 mg administered 1 hour prior to induction of anesthesia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Postoperative nausea and vomiting, treatment:</b> IV: 4 mg as a single dose for failure when an agent from a different class was utilized as prophylaxis <b>or</b> 1 mg may be effective when a prophylactic agent was not utilized (Gan 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Radiation-induced nausea and vomiting, prevention:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Total body irradiation: Oral: 8 mg administered 1 to 2 hours before each daily fraction of radiotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Single high-dose fraction radiotherapy to abdomen: Oral: 8 mg administered 1 to 2 hours before irradiation, then 8 mg every 8 hours after first dose for 1 to 2 days after completion of radiotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Daily fractionated radiotherapy to abdomen: Oral: 8 mg administered 1 to 2 hours before irradiation, then 8 mg 8 hours after first dose for each day of radiotherapy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Nausea and vomiting of pregnancy, severe or refractory:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 8 mg administered over 15 minutes every 12 hours (Arsenault 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: 8 mg every 12 hours (Arsenault 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: No dosage adjustment is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: No dosage adjustment is necessary; however, there is no experience for oral ondansetron in renal impairment beyond first day administration (has not been studied beyond day 1)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Mild to moderate impairment: No dosage adjustment necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Severe impairment (Child-Pugh C):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: Day 1: Maximum daily dose: 8 mg/day; however, according to the manufacturer&rsquo;s labeling there is no experience beyond first-day administration (has not been studied beyond day 1)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral: Maximum daily dose: 8 mg/day</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203680\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Film, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zuplenz: 4 mg (1 ea [DSC], 10 ea [DSC], 30 ea); 8 mg (1 ea [DSC], 10 ea [DSC], 30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zofran: 40 mg/20 mL (20 mL [DSC]) [contains methylparaben, propylparaben]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg/2 mL (2 mL); 40 mg/20 mL (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride [strength expressed as base, preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg/2 mL (2 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 12 mg/50 mL in NaCl 0.9% (50 mL); 16 mg/50 mL in NaCl 0.9% (50 mL); 8 mg/50 mL in NaCl 0.9% (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zofran: 4 mg/5 mL (50 mL) [strawberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg/5 mL (50 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 24 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride [strength expressed as base]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zofran: 4 mg, 8 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg, 8 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Disintegrating, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zofran ODT: 4 mg, 8 mg [contains aspartame, methylparaben sodium, propylparaben sodium; strawberry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 4 mg, 8 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203666\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060739\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral (all dosage forms): May administer without regard to meals. Administer 30 minutes prior to chemotherapy, 1 to 2 hours prior to radiotherapy, and 1 hour prior to induction of anesthesia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Orally disintegrating tablet (Zofran ODT): Do not remove from blister until needed. Peel backing off the blister; do not push tablet through foil backing. Using dry hands, place tablet on tongue and allow to dissolve; swallow with saliva (no need to administer with liquids).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Soluble film (Zuplenz): Do not remove from pouch until immediately before use. Using dry hands, place film on top of tongue and allow to dissolve (4 to 20 seconds). Swallow with or without liquid. If using more than one film, allow each film to dissolve completely before administering the next film.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IVPB infusion:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Prevention of chemotherapy-induced nausea and vomiting: Infuse over 15 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Cyclic vomiting syndrome: Infuse over 15 to 30 minutes (Fleischer 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV push: May be administered undiluted IV over 2 to 5 minutes for prevention of PONV</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: Administer as undiluted injection.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203700\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral soluble film: Store between 20&deg;C and 25&deg;C (68&deg;F and 77&deg;F). Store pouches in cartons; keep film in individual pouch until ready to use.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral solution: Store between 15&deg;C and 30&deg;C (59&deg;F and 86&deg;F). Protect from light.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tablet: Store between 2&deg;C and 30&deg;C (36&deg;F and 86&deg;F).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vial: Store between 2&deg;C and 30&deg;C (36&deg;F and 86&deg;F). Protect from light. Chemically and physically stable when mixed in D5W or NS for 48 hours at room temperature; however, diluents generally do not contain a preservative and sterile precautions should be observed. After dilution, do not use beyond 24 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Premixed bag in D<sub>5</sub>W: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F), excursions permitted from 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); may refrigerate; avoid freezing and excessive heat; protect from light.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1060738\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Orally disintegrating tablets, oral solution, oral tablets: Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy (FDA approved in ages &ge;4 years and adults); prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy (including cisplatin) (FDA approved in adults); prevention of nausea and vomiting associated with radiotherapy (FDA approved in adults); prevention of postoperative nausea and vomiting (FDA approved in adults); has also been used in the treatment of severe or refractory nausea and vomiting of pregnancy</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Soluble Film (Zuplenz): Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy (FDA approved in ages &ge;4 years and adults); prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy or radiotherapy (FDA approved in adults); prevention of postoperative nausea and vomiting (PONV) (FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy [including high-dose cisplatin] (FDA approved in ages &ge;6 months and adults); prevention of postoperative nausea and vomiting (FDA approved in ages &ge;1 month and adults); has also been used in the treatment of acute gastroenteritis, cyclic vomiting syndrome, and severe or refractory nausea and vomiting of pregnancy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203765\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ondansetron may be confused with dolasetron, granisetron, palonosetron </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Zofran may be confused with Zantac, Zosyn</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203762\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Agitation (oral), anxiety (oral), dizziness, drowsiness (IV), fatigue (oral), headache (more common in oral), malaise (oral), paresthesia (IV), sedation (IV), sensation of cold (IV)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Pruritus, skin rash </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Constipation, diarrhea (more common in oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Gynecologic disease (oral), urinary retention (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hepatic: Increased serum ALT (&gt;2 times ULN; transient), increased serum AST (&gt;2 times ULN; transient)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Injection site reaction (IV, includes burning sensation at injection site, erythema at injection site, injection site pain) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Hypoxia (oral)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Fever </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Rare but important or life-threatening: Abdominal pain, accommodation disturbance, atrial fibrillation, cardiorespiratory arrest (IV), depression of ST segment on ECG, dyspnea, extrapyramidal reaction (IV), flushing, hepatic failure (when used with other hepatotoxic medications), hiccups, hypersensitivity reaction, hypokalemia, hypotension, laryngospasm (IV), liver enzyme disorder, mucosal tissue reaction, myocardial infarction, neuroleptic malignant syndrome, positive lymphocyte transformation test, prolonged Q-T interval on ECG (dose dependent), second-degree atrioventricular block, serotonin syndrome, shock (IV), Stevens-Johnson syndrome, supraventricular tachycardia, syncope, tachycardia, tonic-clonic seizures, torsades de pointes, transient blindness (lasted &le;48 hours), transient blurred vision (following infusion), vascular occlusive events, ventricular premature contractions, ventricular tachycardia, weakness </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203687\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to ondansetron or any component of the formulation; concomitant use with apomorphine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203670\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions (including anaphylaxis and bronchospasm) have been reported; discontinue if hypersensitivity occurs. Use with caution in patients allergic to other 5-HT3 receptor antagonists; cross-reactivity has been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation: ECG changes, including dose-dependent QT interval prolongation, have been observed with ondansetron use. Cases of torsade de pointes have also been reported. Selective 5-HT<sub>3</sub> antagonists, including ondansetron, have been associated with a number of dose-dependent increases in ECG intervals (eg, PR, QRS duration, QT/QTc, JT), usually occurring 1 to 2 hours after IV administration. Single doses &gt;16 mg ondansetron IV are no longer recommended due to the potential for an increased risk of QT prolongation. In most patients, these changes are not clinically relevant; however, when used in conjunction with other agents that prolong these intervals or in those at risk for QT prolongation, arrhythmia may occur. When used with agents that prolong the QT interval (eg, Class I and III antiarrhythmics) or in patients with cardiovascular disease, clinically relevant QT interval prolongation may occur resulting in torsades de pointes. A number of trials have shown that 5-HT<sub>3</sub> antagonists produce QT interval prolongation to variable degrees. Avoid ondansetron use in patients with congenital long QT syndrome. Use caution and monitor ECG in patients with other risk factors for QT prolongation (eg, medications known to prolong QT interval, electrolyte abnormalities [hypokalemia or hypomagnesemia], heart failure, bradyarrhythmias, and cumulative high-dose anthracycline therapy). Reduction in heart rate may also occur with the 5-HT<sub>3</sub> antagonists. IV formulations of 5-HT<sub>3</sub> antagonists have more association with ECG interval changes, compared to oral formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Serotonin syndrome: Serotonin syndrome has been reported with 5-HT<sub>3</sub> receptor antagonists, predominantly when used in combination with other serotonergic agents (eg, SSRIs, SNRIs, MAOIs, mirtazapine, fentanyl, lithium, tramadol, and/or methylene blue). Some of the cases have been fatal. The majority of serotonin syndrome reports due to 5-HT<sub>3</sub> receptor antagonist have occurred in a postanesthesia setting or in an infusion center. Serotonin syndrome has also been reported following overdose of ondansetron. Monitor patients for signs of serotonin syndrome, including mental status changes (eg, agitation, hallucinations, delirium, coma); autonomic instability (eg, tachycardia, labile blood pressure, diaphoresis, dizziness, flushing, hyperthermia); neuromuscular changes (eg, tremor, rigidity, myoclonus, hyperreflexia, incoordination); gastrointestinal symptoms (eg, nausea, vomiting, diarrhea); and/or seizures. If serotonin syndrome occurs, discontinue 5-HT<sub>3</sub> receptor antagonist treatment and begin supportive management.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Dose limitations are recommended for patients with severe hepatic impairment (Child-Pugh class C); use with caution in mild-moderate hepatic impairment; clearance is decreased and half-life increased in hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylalanine: Orally-disintegrating tablets contain phenylalanine.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chemotherapy-associated emesis: Antiemetics are most effective when used prophylactically (Roila 2016). If emesis occurs despite optimal antiemetic prophylaxis, re-evaluate emetic risk, disease, concurrent morbidities and medications to assure antiemetic regimen is optimized (ASCO [Hesketh 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Ileus or gastric distention: Ondansetron does not stimulate gastric or intestinal peristalsis (do not use in place of nasogastric suction). Ondansetron may mask progressive ileus and/or gastric distension; monitor for decreased bowel activity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203750\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP1A2 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein/ABCB1; <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203675\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12659&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Apomorphine: Antiemetics (5HT3 Antagonists) may enhance the hypotensive effect of Apomorphine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bosentan: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Moderate): May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dabrafenib: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible.  If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Enzalutamide: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided.  Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hydroxychloroquine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MetFORMIN: Ondansetron may increase the serum concentration of MetFORMIN. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mitotane: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Panobinostat: Ondansetron may enhance the arrhythmogenic effect of Panobinostat. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pitolisant: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Combined use of pitolisant with a CYP3A4 substrate that has a narrow therapeutic index should be avoided. Other CYP3A4 substrates should be monitored more closely when used with pitolisant.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probucol: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Moderate Risk) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying): May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): May enhance the QTc-prolonging effect of other QTc-Prolonging Agents (Moderate Risk). Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sarilumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: Antiemetics (5HT3 Antagonists) may enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome. <b> Exceptions: </b>Nicergoline.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Siltuximab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">St John's Wort: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tapentadol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of Tapentadol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">TraMADol: Antiemetics (5HT3 Antagonists) may diminish the analgesic effect of TraMADol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vinflunine: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Xipamide: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203703\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Tablet: Food slightly increases the extent of absorption. Management: Administer without regard to meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203677\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203690\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Ondansetron readily crosses the human placenta in the first trimester of pregnancy and can be detected in fetal tissue (Siu 2006). Due to pregnancy-induced physiologic changes, clearance of ondansetron may increase as pregnancy progresses (Lemon 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Although ondansetron has been evaluated for the treatment of nausea and vomiting of pregnancy, current guidelines note data related to fetal safety is conflicting (ACOG 2015); ondansetron is generally reserved for use when other agents have failed (Arsenault 2002). Because a dose-dependent QT-interval prolongation occurs with use, the manufacturer recommends ECG monitoring in patients with electrolyte abnormalities (which can be associated with some cases of NVP; Koren 2012). An international consensus panel recommends that 5-HT<sub>3</sub> antagonists (including ondansetron) should not be withheld in pregnant patients receiving chemotherapy for the treatment of gynecologic cancers, when chemotherapy is given according to general recommendations for chemotherapy use during pregnancy (Amant 2010).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13786892\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Closely monitor patients &lt;4 months of age; baseline ECG (if applicable); serum electrolytes (potassium/magnesium); emesis episodes. Monitor for signs of serotonin syndrome; monitor for decreased bowel activity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203669\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Ondansetron is a selective 5-HT<sub>3</sub>-receptor antagonist which blocks serotonin, both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203686\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: ~30 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: 100%; nonlinear absorption occurs with increasing oral doses; Zofran ODT tablets are bioequivalent to Zofran tablets; absorption does not occur via oral mucosa </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infants and Children: Surgical patients:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">1 to 4 months: 3.5 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">5 to 24 months: 2.3 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">3 to 12 years: 1.65 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents: Cancer patients: 4 to 18 years: 1.9 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: 1.9 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: 70% to 76%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Extensively hepatic via hydroxylation, followed by glucuronide or sulfate conjugation; CYP1A2, CYP2D6, and CYP3A4 substrate; some demethylation occurs</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability: Oral: 50% to 70% due to some first-pass metabolism; in cancer patients (adults) 85% to 87% bioavailability possibly related to changes in metabolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Children: Cancer patients: Children and Adolescents: 4 to 18 years: 2.8 hours; Surgical patients: Infants 1 to 4 months: 6.7 hours; Infants and Children 5 months to 12 years: 2.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">Adults: 3 to 6 hours; Mild-to-moderate hepatic impairment (Child-Pugh classes A and B): 12 hours; Severe hepatic impairment (Child-Pugh class C): 20 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: Oral: ~2 hours; Oral soluble film: ~1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (44% to 60% as metabolites, ~5% as unchanged drug); feces (~25%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cancer patients: Children and Adolescents 4 to 18 years: 0.599 L/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Surgical patients: Infants and Children: 1 to 4 months: 0.401 L/kg/hour; 5 to 24 months: 0.581 L/kg/hour; 3 to 12 years: 0.439 L/kg/hour</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adult (normal): 19 to 40 years: 0.381 L/kg/hour; 61 to 74 years: 0.319 L/kg/hour; &gt;75 years: 0.262 L/kg/hour </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203685\" class=\"block exp drugH1Div\"><span class=\"drugH1\">Extemporaneous Preparations</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Commercial oral solution is available (0.8 mg/mL)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">If commercial oral solution is unavailable, a 0.8 mg/mL syrup may be made with ondansetron tablets, Ora-Plus&reg; (Paddock), and any of the the following syrups: Cherry syrup USP, Syrpalta&reg; (HUMCO), Ora-Sweet&reg; (Paddock), or Ora-Sweet&reg; Sugar-Free (Paddock). Crush ten 8 mg tablets in a mortar and reduce to a fine powder (flaking of the tablet coating occurs). Add 50 mL Ora-Plus&reg; in 5 mL increments, mixing thoroughly; mix while adding the chosen syrup in incremental proportions to <b>almost</b> 100 mL; transfer to a calibrated bottle, rinse mortar with syrup, and add sufficient quantity of syrup to make 100 mL. Label &quot;shake well&quot; and &quot;refrigerate&quot;. Stable for 42 days refrigerated (Trissel, 1996).</p>\n    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">Rectal suppositories: Calibrate a suppository mold for the base being used. Determine the displacement factor (DF) for ondansetron for the base being used (Fattibase&reg; = 1.1; Polybase&reg; = 0.6). Weigh the ondansetron tablet(s). Divide the tablet weight by the DF; this result is the weight of base displaced by the drug. Subtract the weight of base displaced from the calculated weight of base required for each suppository. Grind the ondansetron tablets in a mortar and reduce to a fine powder. Weigh out the appropriate weight of suppository base. Melt the base over a water bath (&lt;55&deg;C). Add the ondansetron powder to the suppository base and mix well. Pour the mixture into the suppository mold and cool. Stable for at least 30 days refrigerated (Tenjarla, 1998).</p>\n    <div class=\"reference\">Tenjarla SN, Ward ES, and Fox JL, &quot;Ondansetron Suppositories: Extemporaneous Preparation, Drug Release, Stability and Flux Through Rabbit Rectal Membrane,&quot; <i>Int J Pharm Compound</i>, 1998, 2(1):83-8. </div>\r\n\n    <div class=\"reference\">Trissel LA, <i>Trissel's Stability of Compounded Formulations</i>, Washington, DC: American Pharmaceutical Association, 1996.</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203689\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Film</b> (Zuplenz Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (30): $1,158.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (30): $1,158.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ondansetron HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/2 mL (2 mL): $0.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg/20 mL (20 mL): $6.05</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ondansetron HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/5 mL (50 mL): $239.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Ondansetron HCl-NaCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg/50 mL 0.9% (50 mL): $7.26</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">12 mg/50 mL 0.9% (50 mL): $7.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">16 mg/50 mL 0.9% (50 mL): $8.70</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Zofran Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg/5 mL (50 mL): $283.22</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (Ondansetron Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (30): $668.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (30): $1,113.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, orally-disintegrating</b> (Zofran ODT Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (1): $26.33</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (1): $43.85</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ondansetron HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (30): $742.25</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (30): $1,209.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">24 mg (1): $105.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Zofran Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">4 mg (30): $837.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg (30): $1,394.50</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F203692\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Apulset (BD);</li>\n      <li>Avessa (LU);</li>\n      <li>Cedantron (ID);</li>\n      <li>Cetron (AR);</li>\n      <li>Danac (MX);</li>\n      <li>Dantron (TH, ZA);</li>\n      <li>Emeset (IN, LK);</li>\n      <li>Emetron (HU);</li>\n      <li>Emiset (BD);</li>\n      <li>Emistop (PH);</li>\n      <li>Emizof (IE);</li>\n      <li>Emodan (PH);</li>\n      <li>Enset (PH);</li>\n      <li>Finaber (PY);</li>\n      <li>Frazon (ID);</li>\n      <li>Glotron (ID);</li>\n      <li>Invomit (ID);</li>\n      <li>Izofran (CL, UY);</li>\n      <li>Lartron (MX);</li>\n      <li>Modifical (CO, EC);</li>\n      <li>Narfoz (ID);</li>\n      <li>Nausedron (BR);</li>\n      <li>Ofran (LK);</li>\n      <li>Ondak (CO);</li>\n      <li>Ondant (KR);</li>\n      <li>Ondavell (ID, PH, SG, TH);</li>\n      <li>Ondawi (LK);</li>\n      <li>Ondaz (AU);</li>\n      <li>Ondem (UA);</li>\n      <li>Ondran (IE);</li>\n      <li>Onetic (ID);</li>\n      <li>Onsat (BD);</li>\n      <li>Onset-8 (PH);</li>\n      <li>Onsetron (KR);</li>\n      <li>Onsett (TZ);</li>\n      <li>Onsia (TH);</li>\n      <li>Onzet (PH);</li>\n      <li>Onzod (TW);</li>\n      <li>Osetron (AU, BD);</li>\n      <li>Periset (BD);</li>\n      <li>Setofilm (ES, GB);</li>\n      <li>Setronax (HK, MY, SG, VN);</li>\n      <li>Trondamet (HK);</li>\n      <li>Vomceran (ID);</li>\n      <li>Vometron (ID);</li>\n      <li>Vomiof (IN);</li>\n      <li>Vomiz (TW);</li>\n      <li>Yatrox (ES);</li>\n      <li>Yunorm (UA);</li>\n      <li>Zemitron (QA);</li>\n      <li>Zetron (TH);</li>\n      <li>Zilfujim (AU);</li>\n      <li>Zofetron (UA);</li>\n      <li>Zofran (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CN, CY, CZ, DE, DK, EC, EE, EG, ES, ET, FI, GB, GH, GM, GN, GY, HK, HN, HR, HU, ID, IE, IL, IQ, IR, IS, IT, JM, JO, JP, KE, KR, KW, LB, LR, LT, LU, LV, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, NZ, OM, PE, PH, PK, PL, PT, PY, QA, RU, SA, SC, SD, SE, SI, SK, SL, SN, SR, SY, TN, TR, TT, TW, TZ, UA, UG, VE, VN, YE, ZM, ZW);</li>\n      <li>Zofran Melt (AE, BH, KW, QA, SA);</li>\n      <li>Zofran ODT (BB);</li>\n      <li>Zofran Zydis (CR, DO, GT, KR, NI, NZ, PA, SV);</li>\n      <li>Zofron (GR);</li>\n      <li>Zophren (FR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Al-Ansari K, Alomary S, Abdulateef H, et al, &quot;Metoclopramide Versus Ondansetron for the Treatment of Vomiting in Children With Acute Gastroenteritis,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2011, 53(2):156-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/21788756/pubmed\" target=\"_blank\" id=\"21788756\">21788756</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amant F, Van Calsteren K, Halaska MJ, et al. Gynecologic cancers in pregnancy: guidelines of an international consensus meeting. <i>Int J Gynecol Cancer</i>. 2009;19(suppl 1):S1-S12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/19509538/pubmed\" target=\"_blank\" id=\"19509538\">19509538</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American College of Obstetrics and Gynecology (ACOG). Practice Bulletin No. 153: Nausea and Vomiting of Pregnancy. <i>Obstet Gynecol</i>. 2015;126(3):e12-e24. doi: 10.1097/AOG.0000000000001048.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/26287788/pubmed\" target=\"_blank\" id=\"26287788\">26287788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderka M, Mitchell AA, Louik C, et al, &quot;Medications Used to Treat Nausea and Vomiting of Pregnancy and the Risk of Selected Birth Defects,&quot; <i>Birth Defects Res A Clin Mol Teratol</i>, 2012, 94(1):22-30.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/22102545/pubmed\" target=\"_blank\" id=\"22102545\">22102545</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Applegate GL, Mittal BB, Kletzel M, et al. Outpatient total body irradiation prior to bone marrow transplantation in pediatric patients: a feasibility analysis. <i>Bone Marrow Transplant</i>. 1998;21(7):651-652.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/9578303 /pubmed\" target=\"_blank\" id=\"9578303 \">9578303 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arsenault MY, Lane CA, MacKinnon CJ, et al. The management of nausea and vomiting of pregnancy. <i>J Obstet Gynaecol Can</i>. 2002;24(10):817-831.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/12405123/pubmed\" target=\"_blank\" id=\"12405123\">12405123</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Prestrud AA, Hesketh PJ, et al, &quot;Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update,&quot; <i>J Clin Oncol</i>, 2011, 29(31):4189-98.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/21947834/pubmed\" target=\"_blank\" id=\"21947834\">21947834</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bredeson C, Perry G, Martens C, et al. Outpatient total body irradiation as a component of a comprehensive outpatient transplant program. <i>Bone Marrow Transplant</i>. 2002;29(8):667-671.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/12180111 /pubmed\" target=\"_blank\" id=\"12180111 \">12180111 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carden PA, Mitchell SL, Waters KD, et al, &ldquo;Prevention of Cyclophosphamide/Cytarabine-Induced Emesis With Ondansetron in Children With Leukemia,&rdquo; <i>J Clin Oncol</i>, 1990, 8(9):1531-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/2144019/pubmed\" target=\"_blank\" id=\"2144019\">2144019</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention, &quot;Managing Acute Gastroenteritis Among Children: Oral Rehydration, Maintenance, and Nutritional Therapy,&quot; <i>MMWR Recomm Rep</i>, 2003, 52(RR-16):1-16.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DeCamp LR, Byerley JS, Doshi N, et al, &quot;Use of Antiemetic Agents in Acute Gastroenteritis: A Systematic Review and Meta-analysis,&quot; <i>Arch Pediatr Adolesc Med</i>, 2008, 162(9):858-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/18762604/pubmed\" target=\"_blank\" id=\"18762604\">18762604</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Holdsworth M, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2013;60(7):1073-1082.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/23512831/pubmed\" target=\"_blank\" id=\"23512831\">23512831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Einarson A, Maltepe C, Navioz Y, et al, &quot;The Safety of Ondansetron for Nausea and Vomiting of Pregnancy: A Prospective Comparative Study,&quot; <i>BJOG</i>, 2004, 111(9):940-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/15327608/pubmed\" target=\"_blank\" id=\"15327608\">15327608</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Farah RA, Aquino VM, Munoz LL, Sandler ES. Safety and cost-effectiveness of outpatient total body irradiation in pediatric patients undergoing stem cell transplantation. <i>J Pediatr Hematol Oncol</i>. 1998;20(4):319-321.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/9703004 /pubmed\" target=\"_blank\" id=\"9703004 \">9703004 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ferreira E, Gillet M, Leli&egrave;vre J, et al, &quot;Ondansetron Use During Pregnancy: A Case Series,&quot; <i>J Popul Ther Clin Pharmacol</i>, 2012, 19(1):e1-e10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/22267256/pubmed\" target=\"_blank\" id=\"22267256\">22267256</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fleisher DR, &ldquo;Management of Cyclic Vomiting Syndrome,&rdquo; <i>J Pediatr Gastrenterol Nutr</i>, 1994, 21(Suppl 1):S52-6.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freedman SB, Adler M, Seshadri R, et al, &quot;Oral Ondansetron for Gastroenteritis in a Pediatric Emergency Department,&quot;<i> N Engl J Med</i>, 2006, 354(16):1698-705.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/16625009/pubmed\" target=\"_blank\" id=\"16625009\">16625009</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gan TJ, Meyer TA, Apfel CC, et al, &quot;Society for Ambulatory Anesthesia Guidelines for the Management of Postoperative Nausea and Vomiting,&quot; <i>Anesth Analg, 2007, 105(6):1615-28.</i><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/18042859/pubmed\" target=\"_blank\" id=\"18042859\">18042859</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2017;35(28):3240-3261.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Holdsworth MT, Raisch DW, and Frost J, &quot;Acute and Delayed Nausea and Emesis Control in Pediatric Oncology Patients,&quot; <i>Cancer</i>, 2006, 106(4):931-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/16404740/pubmed\" target=\"_blank\" id=\"16404740\">16404740</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koren G, &quot;Motherisk Update. Is Ondansetron Safe for Use During Pregnancy?&quot; <i>Can Fam Physician</i>, 2012, 58(10):1092-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/23064917/pubmed\" target=\"_blank\" id=\"23064917\">23064917</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lemon LS, Zhang H, Hebert MF, et al. Ondansetron exposure changes in a pregnant woman. <i>Pharmacotherapy</i>. 2016;36(9):e139-e141. doi: 10.1002/phar.1796.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/27374186/pubmed\" target=\"_blank\" id=\"27374186\">27374186</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Li BU, Lefevre F, Chelimsky GG, et al, &quot;North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Consensus Statement on the Diagnosis and Management of Cyclic Vomiting Syndrome,&quot; <i>J Pediatr Gastroenterol Nutr</i>, 2008, 47(3):379-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/18728540/pubmed\" target=\"_blank\" id=\"18728540\">18728540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marty M, Pouillart P, Scholl S, et al, &ldquo;Comparison of the 5-hydroxytryptamine 3 (Serotonin) Antagonist Ondansetron (GR 38032F) With High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis,&rdquo; <i>N Engl J Med</i>, 1990, 322(12):816-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/2137902 /pubmed\" target=\"_blank\" id=\"2137902 \">2137902 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mondick JT, Johnson BM, Haberer LJ, et al, &quot;Population Pharmacokinetics of Intravenous Ondansetron in Oncology and Surgical Patients Aged 1-48 Months,&quot;<i> Eur J Clin Pharmacolm</i>, 2010, 66(1):77-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/19798490/pubmed\" target=\"_blank\" id=\"19798490\">19798490</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murray KL, Wright D, Laxton B, Miller KM, Meyers J, Englebright J. Implementation of standardized pediatric i.v. medication concentrations. <i>Am J Health Syst Pharm</i>. 2014;71(17):1500-1508.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/25147175/pubmed\" target=\"_blank\" id=\"25147175\">25147175</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pasternak B, Svanstr&ouml;m H, and Hviid A, &quot;Ondansetron in Pregnancy and Risk of Adverse Fetal Outcomes,&quot; <i>N Engl J Med</i>, 2013, 368(9):814-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/23445092/pubmed\" target=\"_blank\" id=\"23445092\">23445092</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips RS, Gopaul S, Gibson F, et al, &quot;Antiemetic Medication for Prevention and Treatment of Chemotherapy Induced Nausea and Vomiting in Childhood,&quot; <i>Cochrane Database Syst Rev</i>, 2010, (9):CD007786.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/20824866/pubmed\" target=\"_blank\" id=\"20824866\">20824866</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pinkerton CR, Williams D, Wootton C, et al, &ldquo;5-HT<sub>3</sub> Antagonist Ondansetron - An Effective Outpatient Antiemetic in Cancer Treatment,&rdquo; <i>Arch Dis Child</i>, 1990, 65(8):822-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/2144721/pubmed\" target=\"_blank\" id=\"2144721\">2144721</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F and Del Favero A, &ldquo;Ondansetron Clinical Pharmacokinetics,&rdquo; <i>Clin Pharmacokinet</i>, 1995, 29(2):95-109.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/7586904 /pubmed\" target=\"_blank\" id=\"7586904 \">7586904 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(Suppl 5):v119-v133.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seynaeve C, Schuller J, Buser K, et al, &ldquo;Comparison of the Anti-emetic Efficacy of Different Doses of Ondansetron, Given as Either a Continuous Infusion or a Single Intravenous Dose, in Acute Cisplatin-Induced Emesis,&rdquo; <i>Br J Cancer</i> 1992, 66(1):192-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/1386245/pubmed\" target=\"_blank\" id=\"1386245\">1386245</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Siu SS, Chan MT, and Lau TK, &quot;Placental Transfer of Ondansetron During Early Human Pregnancy,&quot; <i>Clin Pharmacokinet</i>, 2006, 45(4):419-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/16584287/pubmed\" target=\"_blank\" id=\"16584287\">16584287</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spahr-Schopfer IA, Lerman J, Sikich N, et al, &ldquo;Pharmacokinetics of Intravenous Ondansetron in Healthy Children Undergoing Ear, Nose, and Throat Surgery,&rdquo; <i>Clin Pharmacol Ther</i>, 1995, 58(3):316-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/7554705 /pubmed\" target=\"_blank\" id=\"7554705 \">7554705 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spector JI, Lester EP, Chevlen EM, et al, &ldquo;A Comparison of Oral Ondansetron and Intravenous Granisetron for the Prevention of Nausea and Emesis Associated With Cisplatin-Based Chemotherapy,&rdquo; <i>Oncologist</i>, 1998, 3(6):432-438.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/10388135/pubmed\" target=\"_blank\" id=\"10388135\">10388135</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tan PC and Omar SZ, &quot;Contemporary Approaches to Hyperemesis During Pregnancy,&quot; <i>Curr Opin Obstet Gynecol</i>, 2011, 23(2):87-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/ondansetron-pediatric-drug-information/abstract-text/21297474/pubmed\" target=\"_blank\" id=\"21297474\">21297474</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    WHO Pharmaceuticals Newsletter. Ondansetron and serotonin syndrome. 2012; 3:16-21.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zofran tablets (ondansetron) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zofran injection (ondansetron) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zuplenz (ondansetron) [prescribing information]. Raleigh, NC: Midatech Pharma US Inc.; January 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12659 Version 266.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F203706\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F203707\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1060735\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1060729\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F203680\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F203666\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1060739\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F203700\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1060738\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F203765\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F203762\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F203687\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F203670\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F203750\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F203675\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F203703\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F203677\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F203690\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F13786892\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F203669\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F203686\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Extemporaneous Preparations\" href=\"#F203685\" class=\"outlineLink\">Extemporaneous Preparations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F203689\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F203692\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12659|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=ondansetron-drug-information\" class=\"drug drug_general\">Ondansetron: Drug information</a></li><li><a href=\"topic.htm?path=ondansetron-patient-drug-information\" class=\"drug drug_patient\">Ondansetron: Patient drug information</a></li></ul></div></div>","javascript":null}